Ardent Health Inc (NYSE:ARDT)

Q3 2025 Ardent Health Inc Earnings Call Transcript

Nov 13, 2025 / 02:00 PM GMT

Release Date Price: $9.3 (-33.81%)

Transcript 10-Q8-K

Key Points

Positve

Ardent Health Inc (ARDT) reported a 30% year-to-date increase in adjusted EBITDA, indicating strong financial performance.
The company achieved a 5.8% growth in admissions during the third quarter, surpassing the national average.
Revenue grew by 8.8% in the third quarter, or 11.7% excluding a one-time revenue adjustment, showcasing robust top-line growth.
Ardent Health Inc (ARDT) has a strong balance sheet with total available liquidity of $904 million, providing financial flexibility.
The company is implementing an impact program expected to generate over $40 million in annual benefits through cost optimization and efficiency improvements.

Negative

Ardent Health Inc (ARDT) revised its full-year adjusted EBITDA guidance downward to $530 million to $555 million due to persistent industry-wide cost pressures.
Professional fee expenses increased by 11% in the third quarter, contributing significantly to the reduction in EBITDA guidance.
Payer denials have increased, impacting the company's adjusted EBITDA guidance and creating financial headwinds.
The company recorded a $43 million revenue reduction due to a change in accounting estimate, affecting third-quarter financial results.
A $54 million increase in professional and general liability reserves was recorded, primarily due to adverse claims development in the New Mexico market.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

ARDT.N - Ardent Health Inc
Q3 2025 Ardent Health Inc Earnings Call
Nov 13, 2025 / 02:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Ladies and gentlemen, thank you for standing by. My name is Desiree, and I will be your conference operator today. At this time, I would like to welcome everyone to the Arddent Health 3rd quarter 2025 earnings conference call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. If you would like to ask a question during this time, simply press followed by the number 1 on your telephone keypad. If you would like to withdraw a question again, press 1. I would now like to turn the conference over to Dave Steiblo, Senior Vice President of Investor Relations. You may begin.

-----------------------------------------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.